Molnupiravir

🧮 Dose calculator

COVID-19 · Regimen source: FDA Lagevrio (EUA) · 2.1

• • As soon as possible and within 5 days of symptom onset. No renal or hepatic adjustment. Emergency Use Authorization only. FDA Lagevrio (EUA) · 2.1FDA Lagevrio (EUA) · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Lagevrio (EUA) · Boxed Warning

  “Based on findings from animal reproduction studies, LAGEVRIO may cause fetal harm when administered to pregnant individuals.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Lagevrio (EUA) · 8.2

  “Based on the potential for adverse reactions in the infant from LAGEVRIO, breastfeeding is not recommended during treatment with LAGEVRIO and for 4 days after the final dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Lagevrio (EUA) · 8.4

  “The safety and efficacy of LAGEVRIO have not been established in pediatric patients [see Warnings and Precautions (5.3) and Nonclinical Toxicology (13.2) ] .”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Lagevrio (EUA) · 8.5

  “No dosage adjustment is recommended based on age.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Lagevrio (EUA) · 8.3

  “Contraception Females Advise individuals of childbearing potential to use a reliable method of contraception correctly and consistently, as applicable for the duration of treatment and for 4 days after the last dose of LAGEVRIO [see Warnings and Precautions (5.1) ].”